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Background: National prescription databases are important tools in pharmacoepidemiologi-
cal studies investigating potential long-term adverse events after drug use. Palivizumab is a 
biological pharmaceutical used as passive prophylaxis against severe infection with respiratory 
syncytial virus in high-risk children.
Objective: To assess the registration of palivizumab in the Danish National Prescription 
Registry (DNPR) and to examine if palivizumab reimbursement data obtained from the Danish 
Health and Medicines Authority could serve as a supplement to data from the DNPR.
Methods: Registration of palivizumab exposure in the DNPR between 1999 and 2010 was 
compared to two external data sources: registration of palivizumab exposure in medical records, 
and palivizumab reimbursement data.
Results: During the study period, 182 children with palivizumab exposure were registered in the 
DNPR. A total of 207 children were registered for palivizumab reimbursement. The sensitivity 
of palivizumab registration in the DNPR was 26% (20%–34%), and the specificity of no palivi-
zumab registration in the DNPR was 97% (94%–99%), with data from the medical record as 
the reference. Palivizumab registration sensitivity in reimbursement data was 29% (22%–36%), 
and the specificity of no palivizumab registration in the DNPR was 97% (94%–99%), with data 
from the medical record as the reference.
Conclusion: Exposure to palivizumab was underestimated in the DNPR. Reimbursement 
data are a readily accessible data supplement, which only slightly increased the sensitivity 
of palivizumab registration in the DNPR. Our findings underline the need to improve DNPR 
information concerning drugs administered in hospitals.
Keywords: drug; health register; medical records; respiratory syncytial virus; validation 
Introduction
Scandinavia has a long tradition of registry-based epidemiological research,1,2 and 
this research has been facilitated by a long history of national health care registries. 
The tracking of individual disease and prescription data over time is made feasible by 
linking individual information using a unique person identifier known as the Central 
Personal Registration (CPR) number.
Since 1994, the Danish Registry of Medical Product Statistics has maintained pre-
scription drug records for Danish inhabitants. Medicinal products are classified accord-
ing to the World Health Organization (WHO) Anatomical Therapeutic Classification 
System (ATC) coding system. Data have been available to  researchers in an irrevers-
ible encrypted version since 2003 through the Danish National  Prescription  Registry 
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(DNPR), which is available through the  governmental 
 institution, Statistics Denmark. The DNPR contains infor-
mation by CPR number on all drugs prescribed in Danish 
 outpatient pharmacies.3,4 However, drugs administered in-
hospital are not recorded by CPR number, which challenges 
individual studies of drugs that are administered in hospital.
Palivizumab (Synagis®) is a monoclonal antibody used 
as a passive prophylaxis against severe respiratory syncytial 
virus (RSV) infection among high risk children, ie, preterm 
children, children with bronchopulmonary dysplasia (BPD), 
and children with hemodynamically significant heart disease 
(HSHD).5 Palivizumab is administered by monthly intra-
muscular injections (15 mg/kg) throughout the RSV season 
(November to March).
Drug registers may have high public health relevance 
in facilitating studies of long-term drug use consequences. 
Population-based databases like DNPR are unique tools in 
pharmacoepidemiological research given that the registration 
of drug usage is valid, ie, have high measures of sensitivity 
and specificity. Misclassification of drug exposure based 
on registry data will impede studies. We conducted this 
validation study with the overall aim to assess the validity 
of DNPR as data source in studies of palivizumab exposure. 
The primary study objective was to assess the sensitivity 
and specificity of palivizumab exposure in the DNPR using 
medical records data as the reference. Furthermore, we 
assessed if palivizumab reimbursement data could serve as 
a supplement to DNPR data.
Methods
hypotheses
Two hypotheses were tested. Both hypotheses were based 
on the Danish clinical recommendations for palivizumab 
prescriptions:6–8
1. our primary hypothesis was that palivizumab exposure 
among Danish children would be registered in the 
DNPR;
2. secondly, we hypothesized that inclusion of reimburse-
ment data on palivizumab from Danish Health and 
Medicines Authority (DHMA) might serve as a DNPR 
supplement, partly also including in-hospital administra-
tion of palivizumab.
In Denmark, the parents of children prescribed palivi-
zumab usually receive a prescription from their hospital health 
care provider. Subsequently, parents purchase palivizumab at 
a community pharmacy and return to the hospital outpatient 
clinic, or the family physician for their child to receive their 
palivizumab injection. Based on this procedure and because 
palivizumab is administered as monthly injections throughout 
the RSV season we established the first hypothesis. However, 
a child who received palivizumab injection(s) only during 
hospitalization with no subsequent dose(s) after discharge 
would be misclassified as unexposed to palivizumab accord-
ing to DNPR data. Clinicians prescribing palivizumab apply 
to the DHMA for reimbursement. Reimbursement data are 
registered by the patient’s CPR number in an administra-
tive system, together with the diagnosis of the child and the 
name of the physician who applied for the reimbursement.9 
Because palivizumab is costly, we assumed most physicians 
would apply for reimbursement and that the registration of 
reimbursement may also include palivizumab administered 
in-hospital without registration in DNPR.
Data sources
The CPR number was used to link the following registries: 
The Danish Medical Birth Registry,10 DNPR,4 The  Danish 
National Patient Registry,11 The Prescription Database 
of Northern Jutland (PDNJ), The Odense University 
 Pharmacoepidemiological Database (OPED),12,13 and palivi-
zumab reimbursement data.
Research with DNPR data is facilitated by access to 
anonymized in-house data via a safe on-line data portal at 
Statistics Denmark. This policy precludes validation stud-
ies requiring re-identification of patient’s CPR number. The 
OPED and the PDNJ are two regional sub-copies of the 
DNPR covering 40% of the Danish population, and these 
databases permit person-identifiable information for research 
purposes. While DNPR contains data on all prescriptions for 
Danish inhabitants, the OPED and PDNJ contain information 
on all computerized prescription refunds from the Country 
of Funen and Country of Northern Jutland. For registration 
of palivizumab the database contents are similar, includ-
ing information on CPR number, drug (ATC code, name), 
dose(s), and quantity.
OPED and the PDNJ data were used to identify the CPR 
number of a subset of children exposed to palivizumab to 
sample and scrutinize the medical records. Data from medical 
records on palivizumab exposure were exported to Statistics 
Denmark, linked to the in-house data, and anonymized for 
comparison analysis with DNPR.
study population and period
Using the Medical Birth Registry, we identified a study 
base of 778,011 children born between 1997 and 2010 and 
surviving day one after birth. Based on palivizumab recom-
mendations6,8 we identified three cohorts of children for 
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Validity of palivizumab data in the Danish national Prescription registry
whom palivizumab prophylaxis would be recommended, 
but without a registration of palivizumab exposure in the 
DNPR (Figure 1):
1. children born before 26 weeks of gestation were identified 
using information on gestational age from The Medical 
Birth Registry;
2. children with BPD were identified in The National Patient 
Registry by a diagnosis of BPD (International Classifica-
tion of Diseases 10th Revision: P27);
3. children with HSHD were identified by an algorithm 
combining data on HSHD-specific hospitalizations and 
HSHD-specific prescribed drugs adding criteria for age 
at hospitalization and repeated medication. The algorithm 
to identify children with HSHD was developed by a 
specialist in pediatric cardiology.14
The goal was to scrutinize 10% of each of the three 
groups of children, which is generally considered sufficient 
for a validation procedure.15 Because we expected that not 
all medical journals in the hospitals would be identified, we 
randomly oversampled 150 children in each of the three 
groups of palivizumab unexposed children, ie, we sampled 
a larger number than needed. When the goal of identifying 
approximately 10% of the medical records from each group 
of children was achieved medical records collection was 
stopped. An equal fraction of children was included from 
each study year.
Data from the OPED and the PDNJ were furthermore 
collected to identify CPR number in a cohort of children 
exposed to palivizumab (ATC code J06BB16) according to 
DNPR (Figure 1).
Medical record review
Medical records were reviewed at the three large tertiary 
 hospitals in Denmark (Skejby University Hospital in the 
North of Denmark, Odense University Hospital of  Southern 
Denmark and the University Hospital of Copenhagen, 
Rigshospitalet) where children who may be considered for 
palivizumab prophylaxis were expected to be followed. Medi-
cal records were reviewed until the child’s second birthday or 
until the first notification of palivizumab  treatment. Palivi-
zumab exposure status was registered using a standardized 
registration form. If a child was followed in another hospital, 
or only part of the medical record was accessible, the child 
was excluded from the present study.  Reimbursement data 
were obtained from the DHMA.
statistical analyses
The sensitivity and specificity of palivizumab registration in 
the DNPR were estimated and presented with 95% confidence 
intervals (CIs). In a post hoc analysis, the distribution of 
baseline factors in children who had a registration of palivi-
zumab exposure only in the medical records, were compared 
Study base: 778,011
children born 1999–2010 
Not selected for validation: 774,856
High risk children, unexposed to palivizumab according to DPNR   Palivizumab exposed children
according to OPED/PDNJ
        
612 very preterm
children identified through NPR
150 children randomly
oversampled for review of
medical records
 
48 medical records
reviewed and included
in analyses 
1,146 children with BPD
identified through NPR
1,124 children with CHD
identified through NPR
56 children selected
for review of medical record
150 children randomly
oversampled for review of
medical records
150 children randomly
oversampled for review of
medical records 
57 medical records
not reviewed
8 medical records not
reviewed
54 medical records
not reviewed
44 medical records
not reviewed
93 medical records
reviewed and included
in analyses 
106 medical records
reviewed and included
in analyses
96 medical records
reviewed and included
in analyses 
Figure 1 study cohorts and selection of medical records for review.
Abbreviations: DnPr, Danish national Prescription registry; OPED, Odense University Pharmacoepidemiological Database; PDnJ, Prescription Database of northern 
Jutland; nPr, national Patient register; BPD, bronchopulmonary dysplasia; ChD, congenital heart disease.
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using chi-square tests with children who had a registration of 
palivizumab in the DNPR and/or reimbursement data. Data 
analyses were performed using Stata 13.
Ethical approval
No ethical approval is required for Danish registry-based 
studies. The study was approved by the Danish Data 
 Protection Board (J no 2010. 41-5166). The Danish National 
Board of Health approved the access to the medical records 
(J no 7-604-04-2/312/KWH). The DHMA approved access 
to reimbursement data for this study (J no 2012121945).
Results
Figure 1 shows the data collection of medical records for 
palivizumab exposed and unexposed children according 
to DNPR. One child recorded with palivizumab exposure 
in PDNJ and OPED was not registered in the DNPR and 
therefore not included in the analyses.
Palivizumab registration in the DnPr 
with medical records as the reference
Of the 56 children identified through OPED and PDNJ 
with palivizumab registration, only 48 medical records 
were included in the analysis. The remaining eight cases 
were excluded due to incomplete medical record data or 
missing medical records at the hospital. Of the 48 children 
with a registration of palivizumab exposure in the DNPR, 
44 children had a registration of palivizumab in the medical 
records (Table 1).
A total of 295 children’s medical records without palivi-
zumab registration in the DNPR were identified and scru-
tinized for palivizumab exposure. These consisted of: n=93 
medical records among children born ,26 weeks of gesta-
tion, n=106 medical records among children with BPD, and 
n=96 medical records among children with HSHD. Among 
the 295 children, 121 (41%; n=60 immature, n=59 with BPD, 
and 2 children with HSHD) had a registration of palivizumab 
in medical records, yielding a sensitivity of 26% (95% CI 
20%–34%) and a specificity of 97% (94%–99%; Table 1).
Palivizumab reimbursement registration 
with medical records as the reference
A total of 207 children were recorded with reimbursement 
for palivizumab of which 165 were also recorded in the 
DNPR. For 117 (71%) no registration of reimbursement was 
found. The reimbursement data sensitivity when compared 
to medical records data was 29% (95% CI 22%–36%) and 
the specificity was 97% (94%–99%; Table 2).
Palivizumab registration  
in the DnPr with reimbursement  
data as the reference
The comparison of DNPR with data on palivizumab 
reimbursement as reference yielded a sensitivity of 
80% (73%–85%) and a specificity of 99% (99%–100%, 
Table 3).
Post hoc analysis comparing background 
factors in children with registration  
of palivizumab exposure in the medical 
records only with children with 
registration of palivizumab exposure  
in the DnPr/reimbursement data
Significantly different distributions of background fac-
tors between children with palivizumab registration in the 
Table 1 Sensitivity and specificity of palivizumab registration in 
the Danish national Prescription registry with medical records 
as the reference
Medical records
Palivizumab  
exposed
Palivizumab 
unexposed
Total
DNPR
Palivizumab exposed 44 4 48
Palivizumab unexposed 121 174 295
Total 165 178 343
sensitivity or  
specificity (95% CI)
sensitivity 
26% (20%–34%)
Specificity 
97% (94%–99%)
Notes: sensitivity: the probability of palivizumab registration in the DnPD given 
palivizumab exposure in the medical records. Specificity: the probability of no 
palivizumab registration in the DnPr given no palivizumab registration in the 
medical records.
Abbreviations: DNPR, Danish National Prescription Registry; CI, confidence interval.
Table 2 Sensitivity and specificity of palivizumab reimbursement 
registration with medical records as the reference
Medical records
Palivizumab 
exposed
Palivizumab 
unexposed
Total
Reimbursement
Palivizumab exposed 48 4 52
Palivizumab unexposed 117 174 291
Total 165 178 343
sensitivity or 
specificity (95% CI)
sensitivity 
29% (22%–36%)
Specificity 
97% (94%–99%)
Notes: sensitivity: the probability of palivizumab reimbursement registration given 
palivizumab registration in medical records. Specificity: the probability of no palivizumab 
reimbursement registration given no palivizumab registration in medical records.
Abbreviation: CI, confidence interval.
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Validity of palivizumab data in the Danish national Prescription registry
DNPR and/or reimbursement and palivizumab registration 
in medical records were found for gestational age, birth 
weight, fetal growth, and underlying medical conditions 
of the child (Table 4). Children with palivizumab registra-
tion only in medical records had low birth weight, low 
gestational age, were accurate for gestational age, and had 
more often BPD.
Discussion
Palivizumab is a biological pharmaceutical given as a 
passive prophylaxis to vulnerable children. Long-term 
follow-up studies are important for monitoring the safety of 
 palivizumab. This validation study determined that palivi-
zumab exposure was underestimated in the DNPR and was 
also underestimated in reimbursement data.
Medical records were used to access if palivizumab 
was administered in hospitals without a DNPR registra-
tion. We found the sensitivity of palivizumab registration 
in the DNPR to be low and our primary hypothesis that 
palivizumab exposure would be registered in the DNPR 
was not confirmed. The underestimation of palivizumab 
usage was in line with other validation studies of palivi-
zumab data.16,17
Palivizumab is costly, which may be an incentive to 
secure reimbursement. We hypothesized that palivizumab, 
administered in-hospital and therefore not registered in the 
DNPR may be registered by reimbursement data. However, 
the sensitivity of reimbursement data with medical records 
as reference was only slightly better, because no reimburse-
ment was sought for the majority of children exposed to 
palivizumab.
The good accordance observed between data in the DNPR 
and reimbursements was probably explained by discharge 
procedure logistics. In most cases, physicians discharge the 
child, write prescriptions, and apply for reimbursement to 
the family.
Low sensitivity of palivizumab registration in the DNPR 
will cause low or conservative estimates in long-term 
follow-up studies of palivizumab. It may also lead to bias 
if children with palivizumab registration in data sources 
used in epidemiological studies do not represent the overall 
population of palivizumab-exposed children. A post hoc 
analysis determined that more children with low gestational 
age, low birth weight, accurate for gestational age, and BPD 
were found among children with registration of palivizumab 
in medical records. In addition, the fact that the DNPR and/
or reimbursement data failed to identify those children, likely 
reflects the fact that these children may have very long hospi-
talization periods from birth, which increases the probability 
of in-hospital palivizumab exposure.
Data validity for research is important. The present 
study is the first to validate palivizumab registration in the 
DNPR using medical record information and palivizumab 
reimbursement data as references. Numerous prior valida-
tion studies referenced medical records data.16–18 However, 
the registration of drug use in medical records may also 
have limitations. It may be difficult to identify the source of 
data accepted as the “gold standard”. Reimbursement data 
are accessible by DHMA application. In contrast, review of 
medical records to capture the registration of drugs adminis-
tered in-hospital is resource-intensive and time consuming. 
Nonetheless, the inclusion of reimbursement data did not 
increase the study sensitivity.
The present study underlines the need to improve the 
DNPR in terms of registering drugs administered in-hospital 
by CPR number. Governmental initiatives in both Norway 
and Sweden have been established with the aim of creating 
national databases, which include individual information 
on drugs administered in-hospital.19 The same attention is 
warranted in Denmark with the goal of improving DNPR for 
research purposes. The regional database, Odense  University 
Hospital Pharmaco-epidemiological Database, has already 
been established and contains data on in-hospital medica-
tion by CPR.20 Such information will clearly improve future 
registry-based drug studies and are needed on a national 
basis.
Our validation process was subject to limitations. First, 
no “gold standard” data source on palivizumab exposure 
was identified. We used the two data sources available, 
Table 3 Sensitivity and specificity of palivizumab registration 
in the Danish national Prescription registry with palivizumab 
reimbursement registration as the reference
Palivizumab reimbursement data
Palivizumab 
exposed
Palivizumab 
unexposed
Total
DNPR
Palivizumab exposed 165 17 182
Palivizumab unexposed 42 2,658* 2,700
Total 207 2,675 2,882
sensitivity or 
specificity (95% CI)
sensitivity 
80% (73%–85%)
Specificity 
99% (99.0%–99.6%)
Notes: *number of children with a high risk of a severe rsV infection, making them 
potential candidates for palivizumab prophylaxis, but without palivizumab registration 
in the DnPr or reimbursement data. sensitivity: the probability of a palivizumab 
registration in the DNPR given registration of palivizumab reimbursement. Specificity: 
the probability of no palivizumab registration in the DnPr given no registration of 
palivizumab reimbursement.
Abbreviations: CI, confidence interval; RSV, respiratory syncytial virus; DNPR, Danish 
national Prescription registry.
 
Cl
in
ica
l E
pi
de
m
io
lo
gy
 d
ow
nl
oa
de
d 
fro
m
 h
ttp
s:
//w
ww
.d
ov
ep
re
ss
.c
om
/ b
y 
13
0.
22
6.
87
.1
74
 o
n 
13
-D
ec
-2
01
7
Fo
r p
er
so
na
l u
se
 o
nl
y.
Powered by TCPDF (www.tcpdf.org)
                               1 / 1
 Clinical Epidemiology 2015:7submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
310
haerskjold et al
Table 4 Distribution of background factors. Children with palivizumab registration in DnPr or/and reimbursement data versus 
registration in the medical records (only)
Background factor Palivizumab registration  
in DNPR and/or  
reimbursement data 
N=52 (100%)
Palivizumab  
registration in  
medical records only 
N=117 (41%)
No palivizumab registration  
in medical records or  
DNPR or reimbursement 
N=174 (59%)
P-valuea
Plurality 
singleton 
Multiple 
Missing
 
38 (73) 
13 (25) 
1 (2)
 
68 (58) 
37 (32) 
12 (10)
 
128 (74) 
27 (15) 
19 (11)
0.221
Maternal smoking during pregnancy 
Yes 
no 
Missing
 
40 (77) 
4 (8) 
8 (15)
 
22 (19) 
73 (62) 
22 (19)
 
31 (18) 
108 (62) 
35 (20)
0.082
Gestational age 
,32 
32–36 
37+ 
Missing
 
36 (69) 
2 (4) 
11 (21) 
3 (6)
 
102 (88) 
0 (0) 
3 (2) 
12 (10)
 
62 (36) 
11 (6) 
82 (47) 
19 (11)
,0.001
Birth weight 
#1,500 
1,501–2,500 
2,501–4,000 
4,000+ 
Missing
 
37 (71) 
2 (4) 
11 (21) 
0 (0) 
2 (4)
 
101 (86) 
1 (1) 
2 (2) 
1 (1) 
12 (10)
 
66 (38) 
14 (8) 
67 (38) 
8 (5) 
19 (11)
,0.001
Size for gestational age 
sga 
aga 
lga 
Missing
 
21 (41) 
22 (42) 
5 (10) 
4 (8)
 
25 (21) 
78 (67) 
2 (2) 
12 (10)
 
33 (19) 
118 (68) 
4 (2) 
19 (11)
,0.001
Sex 
Male 
Female 
Missing
 
32 (62) 
20 (38) 
0 (0)
 
55 (47) 
50 (43) 
12 (10)
 
94 (54) 
61 (35) 
19 (11)
0.277
Underlying conditionb 
ga ,26 
BPD 
hshD
 
20 (38) 
31 (60) 
15 (29)
 
73 (62) 
89 (76) 
15 (13)
 
39 (22) 
57 (33) 
71 (41)
,0.001 
0.030
0.012
Single parenthood 
no 
Yes 
Missing
 
36 (69) 
7 (13) 
9 (18)
 
93 (79) 
9 (8) 
15 (13)
 
21 (12) 
134 (77) 
19 (11)
 
0.351
Number of older siblings 
0 
1 
.1 
Missing
 
14 (27) 
23 (44) 
15 (29) 
0 (0)
 
39 (33) 
46 (39) 
20 (18) 
12 (10)
 
59 (34) 
53 (30) 
43 (25) 
19 (11)
0.276
Notes: aP-value: differences in distribution of background factors between groups of children with palivizumab registration in DNPR and/or reimbursement (n=52) versus 
children with palivizumab registration in the medical records only (n=117); bchildren can present with more than one condition.
Abbreviations: DnPr, Danish national Prescription registry; sga, small for gestational age; aga, appropriate for gestational age; lga, large for gestational age; 
GA, gestational age; BPD, bronchopulmonary dysplasia; HSHD, hemodynamically significant heart disease; N, number.
medical records, and reimbursement data. Data collection 
in medical records was performed only in the three tertiary 
university hospitals, because we hypothesized that children 
with severe diseases were referred to and followed-up 
at these highly specialized units. Thus, a child may have 
received palivizumab in a non-university hospital after 
being discharged from the university hospital, and this was 
most notable for children with HSHD where only two (out 
of 121) children were registered with palivizumab exposure 
in medical records. The unavailability of medical records to 
confirm palivizumab exposure outside a university hospital 
and also the number of medical records not available at the 
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Validity of palivizumab data in the Danish national Prescription registry
departments is a limitation, which could cause bias in the 
present study. However, the potential bias introduced by 
the selection procedure of medical records was accounted 
for by the additional comparison with national un-selected 
reimbursement data as the reference.
Our access to DNPR was provided by Statistics Denmark. 
Statistics Denmark irreversibly encrypts CPR numbers and 
allows data access only through their own servers. These poli-
cies preclude studies requiring re-identification of patients, 
and hampers medical records comparison. Thus, validation 
procedures in this study were made possible using regional 
sub-databases covering 40% of Denmark.
Pharmacoepidemiological studies with long-term follow-
up are of interest to global public health. The use of the 
CPR number, in combination with a long history of health 
registries in Scandinavian countries offers unique possibili-
ties to carry out valuable pharmacoepidemiological studies 
that may otherwise be considered unethical or too expensive. 
However, the quality of such studies depends on the quality 
of the registration in the drug databases. In conclusion, our 
findings underline the need to improve the information in the 
DNPR concerning drugs administered in-hospital.
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